Gilead's darusentan lowers BP in hard-to-treat patients
US drugmaker Gilead Sciences' darusentan showed signifcant reductions in blood pressure when added to existing antihypertensive regimens in a very difficult-to-treat patient population, according to data presented at the 2009 annual meeting of the American Society of Hypertension, in San Francisco.
The once-daily oral endothelin receptor antagonist is one of the key drug candidates set to help the firm diversify its portfolio away from its current focus on antivirals. The agent yielded mean reductions in trough sitting systolic BP from baseline of 16.5mmHg, 18.1mmHg, 18.1mmHg and 8.6mmHg for the darusentan 50mg, 100mg, 300mg and placebo groups, respectively, after 14 weeks of treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze